BIOLASE, Inc.
BIOL · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.06 | 0.02 |
| FCF Yield | -1,076.04% | -676.83% | -30.23% | -50.21% |
| EV / EBITDA | -0.84 | -0.62 | -2.72 | -1.88 |
| Quality | ||||
| ROIC | -96.63% | -117.12% | -38.67% | -62.04% |
| Gross Margin | 34.02% | 32.83% | 42.18% | 27.10% |
| Cash Conversion Ratio | 0.68 | 0.93 | 1.03 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.85% | 28.61% | 1.21% | -20.97% |
| Free Cash Flow Growth | 49.48% | -75.05% | -35.11% | 0.48% |
| Safety | ||||
| Net Debt / EBITDA | -0.75 | -0.44 | 0.95 | -0.03 |
| Interest Coverage | -7.60 | -9.22 | -7.25 | -7.86 |
| Efficiency | ||||
| Inventory Turnover | 2.84 | 2.05 | 1.75 | 1.49 |
| Cash Conversion Cycle | 101.10 | 157.22 | 194.44 | 259.97 |